ImmuneOncia
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and … Read more
ImmuneOncia (424870) - Net Assets
Latest net assets as of : ₩- KRW
Based on the latest financial reports, ImmuneOncia (424870) has net assets worth ₩- KRW as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩-) and total liabilities (₩-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ImmuneOncia - Net Assets Trend (None–None)
This chart illustrates how ImmuneOncia's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ImmuneOncia (None–None)
The table below shows the annual net assets of ImmuneOncia from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ImmuneOncia's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ImmuneOncia Competitors by Market Cap
The table below lists competitors of ImmuneOncia ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ocean Thermal Energy Corp
PINK:CPWR
|
$53.13K |
|
BENO Holding AG
MU:BENH
|
$53.20K |
|
Cloudweb Inc
PINK:CLOW
|
$53.21K |
|
FRIWO (CEA.SG)
STU:CEA
|
$53.24K |
|
Foncière Euris SA
PA:EURS
|
$53.10K |
|
Cullinan Metals Corp.
OTCQB:CMTNF
|
$53.02K |
|
LEVE3F
SA:LEVE3F
|
$52.94K |
|
BHER39
SA:BHER39
|
$52.87K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImmuneOncia's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ImmuneOncia's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ImmuneOncia utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ImmuneOncia's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImmuneOncia (424870) | ₩- | N/A | N/A | $53.13K |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |